4.8 Article

Distinct Early Serological Signatures Track with SARS-CoV-2 Survival

期刊

IMMUNITY
卷 53, 期 3, 页码 524-+

出版社

CELL PRESS
DOI: 10.1016/j.immuni.2020.07.020

关键词

-

资金

  1. Ragon Institute of MGH, MIT and Harvard
  2. Massachusetts Consortium on Pathogen Readiness (MassCPR)
  3. Bill and Melinda Gates Foundation [235730]
  4. NIAID [U19 AI135995]
  5. Centers for Disease Control and Prevention [CK000490]

向作者/读者索取更多资源

As SARS-CoV-2 infections and death counts continue to rise, it remains unclear why some individuals recover from infection, whereas others rapidly progress and die. Although the immunological mechanisms that underlie different clinical trajectories remain poorly defined, pathogen-specific antibodies often point to immunological mechanisms of protection. Here, we profiled SARS-CoV-2-specific humoral responses in a cohort of 22 hospitalized individuals. Despite inter-individual heterogeneity, distinct antibody signatures resolved individuals with different outcomes. Although no differences in SARS-CoV-2-specific IgG levels were observed, spike-specific humoral responses were enriched among convalescent individuals, whereas functional antibody responses to the nucleocapsid were elevated in deceased individuals. Furthermore, this enriched immunodominant spike-specific antibody profile in convalescents was confirmed in a larger validation cohort. These results demonstrate that early antigen-specific and qualitative features of SARS-CoV-2-specific antibodies point to differences in disease trajectory, highlighting the potential importance of functional antigen-specific humoral immunity to guide patient care and vaccine development.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据